Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ States Set to Sue Monday to Block Paramount-Warner Bros. Deal (Bloomberg) +++ PARAMOUNT SKYDANCE Aktie +3,15%

NANOVIRICIDES Aktie

 >NANOVIRICIDES Aktienkurs 
1.41 EUR    (TradegateBSX)
Ask: 1.44 EUR / 1400 Stück
Bid: 1.38 EUR / 1500 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>NANOVIRICIDES Performance
1 Woche: +13,7%
1 Monat: +13,2%
3 Monate: +55,0%
6 Monate: +21,6%
1 Jahr: +9,5%
laufendes Jahr: +33,8%
>NANOVIRICIDES Aktie
Name:  NANOVIRICIDES NEW DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US6300873022 / A2PSNF
Symbol/ Ticker:  NV3P (Frankfurt)
Kürzel:  FRA:NV3P, ETR:NV3P, NV3P:GR
Index:  -
Webseite:  https://www.nanoviricides..
Profil:  Nanoviricides Inc. is a pioneering biotechnology company that focuses on the development of therapeutics to combat viral infections using nanotechnology. The company is dedicated to creating antiviral nanomedicine known as "nanoviricides," which are ..
>Volltext..
Marktkapitalisierung:  30.4 Mio. EUR
Unternehmenswert:  27.62 Mio. EUR
Umsatz:  -
EBITDA:  -6.67 Mio. EUR
Nettogewinn:  -7.09 Mio. EUR
Gewinn je Aktie:  -0.38 EUR
Schulden:  -
Liquide Mittel:  2.81 Mio. EUR
Operativer Cashflow:  -6.37 Mio. EUR
Bargeldquote:  3.02
Umsatzwachstum:  -
Gewinnwachstum:  22.11%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NANOVIRICIDES
Letzte Datenerhebung:  13.07.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 22.98 Mio. St.
Frei handelbar: 97.23%
Leerverk. Aktien: -
Rückkaufquote: -23.17%
Mitarbeiter: 7
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 344.73%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 3.22
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -79.91%
Eigenkaprendite: -89.97%
>Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
 
13.07.26 - 15:39
 As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th......
08.07.26 - 14:42
 Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company′s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that ......
06.07.26 - 14:42
 As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that ......
29.06.26 - 14:42
 NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development ......
22.06.26 - 15:42
 NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinica......
15.06.26 - 14:39
 As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricide......
08.06.26 - 14:42
 As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides......
26.05.26 - 14:42
 In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares pote......
19.05.26 - 18:48
 NanoViricides closes $2M direct offering (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
19.05.26 - 06:06
 NanoViricides Announces Closing of ~$2 Million Registered Direct Offering (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spec......
18.05.26 - 14:42
 Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes th......
15.05.26 - 14:42
 NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spec......
15.05.26 - 14:24
 NanoViricides GAAP EPS of -$0.09 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
15.05.26 - 14:06
 NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March......
11.05.26 - 14:42
 Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes th......
06.05.26 - 21:42
 D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference (Newsfile)
 
Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2......
04.05.26 - 14:42
 NanoViricides: NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA (Accesswire)
 
SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of......
21.04.26 - 14:43
 Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development......
11.04.26 - 23:48
 NanoViricides seeks FDA′s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
10.04.26 - 03:24
 NanoViricides files for Rare Pediatric Disease Designation for Measles Drug (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Absicht eines Christen, der ein Streitgespräch über die Glaubenswahrheiten führt, muß nicht darauf zielen, den Glauben zu beweisen, sondern den Glauben zu verteidigen. - Hl. Thomas von Aquin
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!